Telix Pharmaceuticals (NASDAQ:TLX) CEO Christian Behrenbruch Acquires 33,435 Shares of Stock

Telix Pharmaceuticals Limited (NASDAQ:TLX) CEO Christian Behrenbruch acquired 33,435 shares of the business’s stock in a transaction dated Wednesday, April 29th. The shares were acquired at an average cost of $14.87 per share, with a total value of $497,178.45. Following the transaction, the chief executive officer owned 20,742,935 shares in the company, valued at approximately $308,447,443.45. This trade represents a 0.16% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Christian Behrenbruch also recently made the following trade(s):

• On Tuesday, April 28th, Christian Behrenbruch acquired 34,500 shares of Telix Pharmaceuticals stock. The shares were acquired at an average cost of $14.48 per share, with a total value of $499,560.00.

Telix Pharmaceuticals Stock Performance

Shares of TLX stock opened at $11.11 on Thursday. Telix Pharmaceuticals Limited has a 1 year low of $6.28 and a 1 year high of $18.49. The firm has a fifty day moving average price of $9.10 and a 200-day moving average price of $8.77. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27.

Telix Pharmaceuticals (NASDAQ:TLX) last issued its quarterly earnings data on Friday, February 20th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The firm had revenue of $206.72 million for the quarter, compared to analysts’ expectations of $421.50 million. As a group, sell-side analysts anticipate that Telix Pharmaceuticals Limited will post 0.09 earnings per share for the current year.

Institutional Investors Weigh In On Telix Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Rhumbline Advisers lifted its holdings in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after acquiring an additional 1,392 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Telix Pharmaceuticals in the 4th quarter valued at about $89,000. IHT Wealth Management LLC bought a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at about $213,000. OLD Mission Capital LLC bought a new position in shares of Telix Pharmaceuticals in the 4th quarter valued at about $111,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Telix Pharmaceuticals in the 3rd quarter valued at about $243,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TLX. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. Citigroup upped their target price on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Monday, April 20th. Wall Street Zen raised shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. Finally, Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $21.13.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.